About Associate Professor David Allsop

Associate Professor David Allsop's research interests are broad in psychopharmacology and clinical trials. He is particularly interested in the endocannabinoid system as it relates to health and well-being and the insights it offers for a biological understanding of diverse disease states. An emerging literature on the many potential therapeutic targets within the endocannabinoid system has led to a specific interest in the psychopharmacology and clinical applications of cannabinoid therapeutics. Working closely with preclinical and clinical colleagues David is interested in translating basic science into clinical evidence with emphasis on targeting the endocannabinoid system for a diverse range of disease states (epilepsy, cancer, mental health, addictions, metabolic diseases and pain). He is also interested in the development of novel targeted cannabinoid therapeutics, and the regulatory frameworks surrounding clinical work in this space.

Associate Professor David Allsop is currently a Director in the Lambert Initiative for Cannabinoid Therapeutics at the University of Sydney.

For more information on Dr Sonia Liu refer to his Academic Profile Online